Fresenius Stays Strong in Tough Times

The health-care company's products are virtually immune to recession, and it has used the strong euro to acquire U.S. drugmaker APP Pharmaceuticals

There's talk of an impending economic slowdown in Germany, but there was no sign of it on a recent sunny day in the affluent Frankfurt suburb of Bad Homburg, nestled at the foot of the forest-covered Taunus mountains. Particularly not at the headquarters of German health-care company Fresenius (FREG.DE), located in a tidy Bad Homburg office park.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.